Five more biotechs file their SEC paperwork as the IPO Class of 2021 swells to 60
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
After last week’s flurry of IPO action ended with two pricings and a SPAC deal, several biotechs got in on the action before the long holiday weekend.
In addition to the two smaller filings that took place on Friday, five other biotechs sent their paperwork to the SEC. Four of those companies — Verve Therapeutics, Century Therapeutics, Ambrx Biopharma and Cyteir Therapeutics — have written in $100 million as their initial placeholder, while HCW Biologics jotted down $50 million.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,900+ biopharma pros reading Endpoints daily — and it's free.